Cartesian Therapeutics (RNAC) Total Debt (2015 - 2023)

Cartesian Therapeutics (RNAC) has 9 years of Total Debt data on file, last reported at $24.0 million in Q2 2023.

• On a quarterly basis, Total Debt fell 7.32% year-over-year to $24.0 million in Q2 2023; TTM through Jun 2023 was $24.0 million, a 7.32% decrease from a year earlier, with the FY2022 full-year figure at $26.3 million, up 2.45% from the prior year.
• Total Debt for Q2 2023 stood at $24.0 million, down from $26.4 million in the prior quarter.
• Over the last five years, Total Debt for RNAC reached as high as $26.4 million in Q1 2023 and fell as low as $14.8 million in Q2 2020.
• Historically, Total Debt has averaged $23.3 million across 5 years, with a median of $24.9 million in 2020.
• Across the five-year window, Total Debt slumped 31.16% in 2020 and jumped 70.04% in 2021, its largest moves.
• Year by year, Total Debt stood at $18.9 million in 2019, then surged by 31.15% to $24.8 million in 2020, then climbed by 3.39% to $25.6 million in 2021, then increased by 2.45% to $26.3 million in 2022, then decreased by 8.53% to $24.0 million in 2023.
• Per Business Quant data, the three most recent Total Debt figures were $24.0 million in Q2 2023, $26.4 million in Q1 2023, and $26.3 million in Q4 2022.